Lapidot, Moshe
Case, Abigail E.
Weisberg, Ellen L.
Meng, Chengcheng
Walker, Sarah R.
Garg, Swati
Ni, Wei http://orcid.org/0000-0002-5729-827X
Podar, Klaus
Hung, Yin P. http://orcid.org/0000-0002-8568-1591
Carrasco, Ruben D.
Knott, Aine
Gokhale, Prafulla C.
Sharma, Sunil
Pozhitkov, Alex
Kulkarni, Prakash
Frank, David A.
Salgia, Ravi
Griffin, James D.
Saladi, Srinivas V.
Bueno, Raphael
Sattler, Martin http://orcid.org/0000-0001-5053-4199
Funding for this research was provided by:
U.S. Department of Health;amp;Human Services | National Institutes of Health (R01-CA120528)
International Mesothelioma Program at Brigham and Women;amp;s Hospital Department of Defense
Article History
Received: 2 April 2021
Revised: 28 April 2021
Accepted: 13 May 2021
First Online: 4 June 2021
Ethics approval and consent to participate
: The human MPM cell lines MS1-MS8 were originally established from discarded tumour specimen at Dana-Farber Cancer Institute. All patients were consented to tissue collection protocols, which were approved by the Institutional Review Board at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute (Boston, MA) in accordance with the Declaration of Helsinki. In vivo mouse experiments were performed at Dana-Farber Cancer Institute after Institutional Animal Care and Use Committee approval in an AAALAC accredited facility.
: Not applicable
: Additional data from this study can be found in the supplementary section.
: R.B is a paid consultant or receives commercial research support from MedGenome, Roche, Verastem, Genentech, Merck, Gritstone, Epizyme, Siemens, Celsius Therapeutics and holds ownership interest (including patents) in Navigation Sciences.
: This work was supported in part by the International Mesothelioma Program at Brigham and Women’s Hospital (R.B.), the Department of Defense (R.B.), the National Institutes of Health (R01-CA120528 (R.B.); R01-CA160979 (D.A.F.)), the Brent Leahey Fund and a generous gift from Ms. Betty Ann Blum (D.A.F.).